On Nov 15, major Wall Street analysts update their ratings for $Biogen (BIIB.US)$, with price targets ranging from $204 to $300.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $204.
Baird analyst Brian Skorney maintains with a buy rating, and adjusts the target price from $294 to $300.
Raymond James analyst Danielle Brill maintains with a hold rating.
Wolfe Research analyst Alexandria Hammond initiates coverage with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
The approach taken by the company to counteract the decline of its core franchise involves focusing on the development of assets aimed at addressing significant unmet needs within challenging indications. It has been noted that the company's pipeline appears to carry a higher clinical risk compared to its major biotech contemporaries, yet this also implies substantial potential value.
The firm believes the application for lecanemab in amyloid-positive early Alzheimer's disease has become more favorable for the European Commission's consideration following the decision to exclude APOE4 homozygotes from the treatment group. This move is seen as enhancing the prospects for approval, with a decision anticipated within a two-month time frame.
Here are the latest investment ratings and price targets for $Biogen (BIIB.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月15日，多家華爾街大行更新了$渤健公司 (BIIB.US)$的評級，目標價介於204美元至300美元。
摩根士丹利分析師Terence Flynn維持持有評級，維持目標價204美元。
貝雅分析師Brian Skorney維持買入評級，並將目標價從294美元上調至300美元。
瑞傑金融分析師Danielle Brill維持持有評級。
沃爾夫研究分析師Alexandria Hammond首次給予持有評級。
此外，綜合報道，$渤健公司 (BIIB.US)$近期主要分析師觀點如下：
公司採取的方法應對核心特許經營業務下滑的措施包括專注於開發資產，旨在滿足具有挑戰性指標中的重大未滿足需求。已經注意到該公司的產品管線似乎具有比其主要生物技術同行更高的臨床風險，但這也意味着具有巨大的潛在價值。
公司認爲萊坎替mab在陽性澱粉樣早期阿爾茨海默病的申請，由於決定將APOE4純合子排除在治療組之外，已經變得更有利於歐洲委員會的考慮。此舉被視爲增強了批准的前景，決定預計將在兩個月的時間框架內做出。
以下爲今日4位分析師對$渤健公司 (BIIB.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
